AstraZeneca's Evusheld Revenue Stream To Dry Up Soon
As FDA Withdraws Authorization Of COVID-19 Therapy
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
